252 related articles for article (PubMed ID: 15073159)
21. Structural insights into Staphylococcus aureus enoyl-ACP reductase (FabI), in complex with NADP and triclosan.
Priyadarshi A; Kim EE; Hwang KY
Proteins; 2010 Feb; 78(2):480-6. PubMed ID: 19768684
[No Abstract] [Full Text] [Related]
22. Selection for high-level resistance by chronic triclosan exposure is not universal.
McBain AJ; Ledder RG; Sreenivasan P; Gilbert P
J Antimicrob Chemother; 2004 May; 53(5):772-7. PubMed ID: 15117935
[TBL] [Abstract][Full Text] [Related]
23. Potent antimicrobial action of triclosan-lysozyme complex against skin pathogens mediated through drug-targeted delivery mechanism.
Hoq MI; Ibrahim HR
Eur J Pharm Sci; 2011 Jan; 42(1-2):130-7. PubMed ID: 21078387
[TBL] [Abstract][Full Text] [Related]
24. Characterization of Pseudomonas aeruginosa enoyl-acyl carrier protein reductase (FabI): a target for the antimicrobial triclosan and its role in acylated homoserine lactone synthesis.
Hoang TT; Schweizer HP
J Bacteriol; 1999 Sep; 181(17):5489-97. PubMed ID: 10464225
[TBL] [Abstract][Full Text] [Related]
25. Discovery of 4-Pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus.
Takahata S; Iida M; Yoshida T; Kumura K; Kitagawa H; Hoshiko S
J Antibiot (Tokyo); 2007 Feb; 60(2):123-8. PubMed ID: 17420562
[TBL] [Abstract][Full Text] [Related]
26. A novel resistance mechanism to triclosan that suggests horizontal gene transfer and demonstrates a potential selective pressure for reduced biocide susceptibility in clinical strains of Staphylococcus aureus.
Ciusa ML; Furi L; Knight D; Decorosi F; Fondi M; Raggi C; Coelho JR; Aragones L; Moce L; Visa P; Freitas AT; Baldassarri L; Fani R; Viti C; Orefici G; Martinez JL; Morrissey I; Oggioni MR;
Int J Antimicrob Agents; 2012 Sep; 40(3):210-20. PubMed ID: 22789727
[TBL] [Abstract][Full Text] [Related]
27. Effects of chronic triclosan exposure upon the antimicrobial susceptibility of 40 ex-situ environmental and human isolates.
Ledder RG; Gilbert P; Willis C; McBain AJ
J Appl Microbiol; 2006 May; 100(5):1132-40. PubMed ID: 16630014
[TBL] [Abstract][Full Text] [Related]
28. Triclosan inhibition of fatty acid synthesis and its effect on growth of Escherichia coli and Pseudomonas aeruginosa.
Escalada MG; Harwood JL; Maillard JY; Ochs D
J Antimicrob Chemother; 2005 Jun; 55(6):879-82. PubMed ID: 15860550
[TBL] [Abstract][Full Text] [Related]
29. Triclosan and antibiotic resistance in Staphylococcus aureus.
Suller MT; Russell AD
J Antimicrob Chemother; 2000 Jul; 46(1):11-8. PubMed ID: 10882683
[TBL] [Abstract][Full Text] [Related]
30. Antimicrobial effect of triclosan and triclosan with Gantrez on five common endodontic pathogens.
Nudera WJ; Fayad MI; Johnson BR; Zhu M; Wenckus CS; Begole EA; Wu CD
J Endod; 2007 Oct; 33(10):1239-42. PubMed ID: 17889698
[TBL] [Abstract][Full Text] [Related]
31. From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria.
Gerusz V; Denis A; Faivre F; Bonvin Y; Oxoby M; Briet S; LeFralliec G; Oliveira C; Desroy N; Raymond C; Peltier L; Moreau F; Escaich S; Vongsouthi V; Floquet S; Drocourt E; Walton A; Prouvensier L; Saccomani M; Durant L; Genevard JM; Sam-Sambo V; Soulama-Mouze C
J Med Chem; 2012 Nov; 55(22):9914-28. PubMed ID: 23092194
[TBL] [Abstract][Full Text] [Related]
32. Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus.
Fan F; Yan K; Wallis NG; Reed S; Moore TD; Rittenhouse SF; DeWolf WE; Huang J; McDevitt D; Miller WH; Seefeld MA; Newlander KA; Jakas DR; Head MS; Payne DJ
Antimicrob Agents Chemother; 2002 Nov; 46(11):3343-7. PubMed ID: 12384334
[TBL] [Abstract][Full Text] [Related]
33. A triclosan-resistant bacterial enzyme.
Heath RJ; Rock CO
Nature; 2000 Jul; 406(6792):145-6. PubMed ID: 10910344
[No Abstract] [Full Text] [Related]
34. Low level of cross-resistance between triclosan and antibiotics in Escherichia coli K-12 and E. coli O55 compared to E. coli O157.
Braoudaki M; Hilton AC
FEMS Microbiol Lett; 2004 Jun; 235(2):305-9. PubMed ID: 15183878
[TBL] [Abstract][Full Text] [Related]
35. Triclosan: a widely used biocide and its link to antibiotics.
Schweizer HP
FEMS Microbiol Lett; 2001 Aug; 202(1):1-7. PubMed ID: 11506900
[TBL] [Abstract][Full Text] [Related]
36. Triclosan-loaded poloxamine micelles for enhanced topical antibacterial activity against biofilm.
Chiappetta DA; Degrossi J; Teves S; D'Aquino M; Bregni C; Sosnik A
Eur J Pharm Biopharm; 2008 Jun; 69(2):535-45. PubMed ID: 18194853
[TBL] [Abstract][Full Text] [Related]
37. Triclosan inhibition of membrane enzymes and glycolysis of Streptococcus mutans in suspensions and biofilms.
Phan TN; Marquis RE
Can J Microbiol; 2006 Oct; 52(10):977-83. PubMed ID: 17110966
[TBL] [Abstract][Full Text] [Related]
38. Biochemical and genetic characterization of the action of triclosan on Staphylococcus aureus.
Slater-Radosti C; Van Aller G; Greenwood R; Nicholas R; Keller PM; DeWolf WE; Fan F; Payne DJ; Jaworski DD
J Antimicrob Chemother; 2001 Jul; 48(1):1-6. PubMed ID: 11418506
[TBL] [Abstract][Full Text] [Related]
39. Correlation between in vitro release from topical delivery vehicles and microbicidal activity of triclosan.
Swart HC; Du Preez JL; De Villiers MM; Lötter AP; Liebenberg W
Pharmazie; 2006 Jan; 61(1):35-40. PubMed ID: 16454204
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of resistance in Salmonella enterica adapted to erythromycin, benzalkonium chloride and triclosan.
Braoudaki M; Hilton AC
Int J Antimicrob Agents; 2005 Jan; 25(1):31-7. PubMed ID: 15620823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
